Form 4: Replimune CEO Sells 10,000 Shares Under 10b5-1 Plan

Replimune Group, Inc. CEO Sushil Patel sold 10,000 shares of common stock for a weighted average price of $11.13 per share under a pre-arranged trading plan.

Summary

• Sushil Patel, Chief Executive Officer and Director of Replimune Group, Inc. (REPL), executed a sale of common stock.
• A total of 10,000 shares of common stock were disposed of on December 2, 2025.
• The shares were sold at a weighted average price of $11.13 per share, with individual transaction prices ranging from $11.00 to $11.26.
• The transaction was conducted pursuant to a Rule 10b5-1(c) trading plan adopted on June 2, 2025.
• Following this sale, Sushil Patel beneficially owns 333,576 shares of Replimune's common stock, which includes restricted stock units.
• Additionally, Mr. Patel holds options to acquire an aggregate of 753,750 shares of common stock, with 331,353 of these options exercisable as of the filing date.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine insider transaction executed under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage personal finances and diversify holdings. It does not inherently signal a positive or negative outlook on the company's fundamentals.

Positives

• The transaction was executed under a Rule 10b5-1(c) trading plan, indicating a pre-scheduled sale rather than a reaction to immediate market conditions, which enhances transparency and reduces concerns about opportunistic insider trading.

Negatives

• The sale reduces the direct equity stake of a key executive, which could be perceived by some investors as a slight reduction in management's alignment with shareholder interests, although mitigated by the 10b5-1 plan.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider sales, which can sometimes lead to negative sentiment if not understood as part of a pre-planned strategy.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Management Comments

• The sales reported were made by the reporting person pursuant to a trading plan adopted on June 2, 2025, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

Industry Context

This insider transaction is specific to Replimune Group, Inc. and does not directly provide insights into broader industry trends or competitive landscape. It reflects an individual executive's pre-planned equity management strategy.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider stock sales is a standard corporate governance practice in the U.S. to allow insiders to sell shares without concerns of trading on material non-public information. This aligns with best practices for executive equity management.

Corporate Governance

Stakeholder Impact

• Shareholders: A minor reduction in direct insider ownership, but the pre-planned nature of the sale under a 10b5-1 plan generally minimizes negative interpretations regarding management's confidence in the company.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider stock sale by the CEO under a 10b5-1 plan. The transaction size (10,000 shares) is relatively small compared to the CEO's total beneficial ownership and options. Such a transaction typically does not reflect a change in the company's fundamental outlook or operational performance and therefore does not warrant a change in investment recommendation. Investors should continue to hold based on the company's underlying business fundamentals rather than this specific insider transaction.

Keywords

Replimune Group, REPL, Sushil Patel, Insider Trading, Form 4, Stock Sale, CEO, 10b5-1 Plan, Equity Transaction